Company intelligence / Profile preview

Alzheon, Inc.

Framingham, Massachusetts, United Statesalzheon.com ↗

Ownership: Private
Development stage: Other

Overview

Alzheon has completed the APOLLOE4 Phase 3 trial of valiltramiprosate (ALZ-801) in early Alzheimer's disease patients with APOE4/4 genotype. The drug showed promising results in Phase 2 with significant reduction in plasma p-tau and preservation of brain volume. Topline data from Phase 3 was expected in Q3 2024, with potential NDA filing in 2024 and commercial launch in 2025.

Therapeutic areas: Neurology
Modalities: Small moleculesoral therapeutics
Industry: Biotech

Drug pipeline

3 assets

valiltramiprosate

2 more assets in the full pipeline.

Partnerships

Collaboration with University of Gothenburg for biomarker analysis

Beyond the preview

Go deeper on Alzheon, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzheon, Inc..